Takeda’s experimental epilepsy drug soticlestat has failed not one but two phase 3 trials – in Dravet syndrome and Lennox-Gastaut syndrome – throwing the future of the programme in doubt.
Voice technology like Amazon’s Alexa is taking some big steps forward in healthcare and in the pharmaceutical world one of the companies working in this area is Eisai.
Japan’s Eisai has a long-term commitment to treating epilepsy, with a series of therapies already on the market - but with many different forms of the disease, requiring different therapeutic appro